An improved understanding of those molecular mechanisms directing NLRP3 activity in tumors as well as the genetic variations that dictate the overall activity of this pathway in various cancers are predicted to lead to novel pharmacologic targets and biomarkers capable of guiding the use of these agents. Here, NLRP3 is linked to cancer.